Organoid Science, a company specializing in organoids, announced on the 18th that it participated in the American Association for Cancer Research (AACR) annual academic conference held in New Orleans, USA from the 8th to the 13th (local time) and completed a presentation.
This presentation was made by Gyeongjin Lee, Chief Technology Officer (CTO) of Organoid Science, who produces patient-specific immune cells through co-cultivation of tumor organoids and patient-derived immune cells and uses them as ADIO (Autologous Organoid), which can evaluate the efficacy of immune checkpoint inhibitors. based Discovery for Immuno-Oncology Drug) was introduced and various examples of collaboration were shared. In addition, the presentation was successfully completed by suggesting the development of antiviral drugs using brain organoids and infectious disease models, tumor research, and the possibility of using organoids as regenerative treatments after radiation treatment.
ADIO, developed independently by Organoid Science, is capable of evaluating all types of anticancer drugs that directly kill cancer cells, including chemical anticancer drugs, targeted anticancer drugs, immune checkpoint inhibitors, immunotherapies such as CAR-T/NK, and radiotherapy, making it suitable for clinical trials. It is an organoid-based efficacy evaluation platform that can dramatically reduce the time and cost required.
In addition, it is said that the event was a success with many visitors’ interest throughout the event period by directly operating an offline booth, demonstrating an imaging-based organoid dispenser automation device, and converting various technologies into local content.
A local official said, “We are experiencing a high level of interest in the field due to inquiries from academic and industrial experts.” We are very much looking forward to achieving good results with global developers, so we will continue to conduct overseas activities to provide optimal solutions. “We will continue,” he said.
Meanwhile, with the success of this AACR as a cornerstone, Organoid Science plans to immediately begin participating in the 2022 American Society of Clinical Oncology (ASCO) to be held in Chicago in June and prepare for its next step to lead organoid technology in the global market.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 202